Lv21
130 积分 2026-06-06 加入
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer
56分钟前
待确认
Biomarkers in High-Grade Serous Ovarian Cancer: Context is everything
22天前
已完结
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
28天前
已关闭
Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies
28天前
已关闭
Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases
28天前
已完结
皖公网安备34019202002308
